Skip to content

Ketamine research published in 2025

Page 19 of 39: studies 361 to 380 of 780, newest first. Back to the ketamine overview

Studies

Ketamine's double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant OCD - A case series.

Indian Journal of Psychiatry June 1, 2025 Suparna Kumar, Jigyansa Ipsita Pattnaik, Udit Kumar Panda et al. 3 citations

About one-third of obsessive-compulsive disorder (OCD) cases show poor response to first-line treatments. Ketamine's role in modulating glutamate, implicated in OCD pathogenesis, warrants investigation. Four adolescents with treatment-resistant OCD received ketamine infusion (0.5 mg/kg) every other day for six sessions with monitoring using the Children's Yale-Brown Obsessive Compulsive Scale...

DOI: 10.4103/indianjpsychiatry_1144_24 (opens in new tab) Full text (opens in new tab) Nmda antagonist Case series Glutamate Treatment-resistant obsessive-compulsive disorder +12

Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight.

Aerospace medicine and human performance June 1, 2025 Craig J Kutz, Amit M Mistry, Charles H Dukes

The transition to exploration missions places a heightened risk on behavioral health in spaceflight. Although serious psychiatric emergencies during spaceflight have been rare, longer duration missions increase the possibility of emergence in latent mental health disorders due to genetic predisposition, increased autonomy, isolation, helplessness, loss of family member, or catastrophic events....

DOI: 10.3357/AMHP.6619.2025 (opens in new tab) Full text (opens in new tab) Earth-independent medical operations Psychiatric emergencies Space medicine: spaceflight Long-duration spaceflight +8

Ketamine differentially affects implicit and explicit memory processes in rats.

Psychopharmacology June 1, 2025 Bahar Yuksel, Zeynep Sen, Gunes Unal 2 citations

Ketamine, a non-competitive NMDA receptor antagonist, produces antidepressant effects at subanesthetic doses. The therapeutic effect, however, is often accompanied by cognitive side effects, including memory impairments. Yet, the specific effects of ketamine on different processes of implicit and explicit memory remain to be elucidated. We examined the effect of an antidepressant dose of...

Enduring modulation of dorsal raphe nuclei regulates (R,S)-ketamine-mediated resilient stress-coping behavior.

Molecular Psychiatry June 1, 2025 Anderson Camargo, Anna Nilsson, Reza Shariatgorji et al. 5 citations

Ketamine may be a novel pharmacologic approach to enhance resilience and protect against stress-related disorders, but the molecular targets underlying this response remain to be fully characterized. The multifunctional protein p11 is crucial in the pathophysiology of depression and antidepressant responses. However, it is still unclear whether p11 plays a role in the pro-resilience effects...

DOI: 10.1038/s41380-024-02853-6 (opens in new tab) Full text (opens in new tab) Mental health Psychopharmacology Stress resilience Ketamine therapy

Intravenous Magnesium Sulfate as an Adjunct to Intravenous Ketamine for Acute Pain: A Case Series.

Journal of Pain & Palliative Care Pharmacotherapy June 1, 2025 Nathan Smith, Sanny Juresic, Kia Lor et al.

Intravenous (IV) magnesium sulfate, a versatile electrolyte, plays a pivotal role across various medical domains. From cardiac care to obstetrics, gastrointestinal to pulmonary therapies, the impact is far-reaching among acute care services. Notably, in the postoperative phase of care, it shares intriguing similarities with ketamine as an NMDA receptor antagonist. This case series describes the...

The antidepressant-like activity of ketamine in the rat chronic mild stress model requires activation of cortical 5-HT 1A receptors.

Behavioural Pharmacology June 1, 2025 Ronan Depoortère, Mariusz Papp, Piotr Gruca et al. 2 citations

Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia (CMS-induced sucrose consumption deficit) and attenuates working memory deficit (novel object recognition: NOR) following both systemic (intraperitoneal, i.p.) administration or local administration in the prefrontal cortex (PFC). However, the...

DOI: 10.1097/FBP.0000000000000809 (opens in new tab) Full text (opens in new tab) Biased agonist Chronic mild stress Rat Depression treatment +3

Esketamine Nasal Spray in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

Clinical Pharmacology & Therapeutics June 1, 2025 Zhibin Wang, Lili Jiang, Wenzhuang Ma et al. 8 citations

Despite being approved by the US FDA and the EU European Medicines Agency, the performance of esketamine nasal spray as an adjunctive therapy with an antidepressant in major depressive disorder is still controversial. Comprehensive retrieval in Embase, Pubmed, and Web of Science was conducted to identify randomized controlled trials comparing esketamine nasal spray versus control in major...

DOI: 10.1002/cpt.3555 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Medical breakthrough Antidepressants +1

The Effect of Ketamine-Assisted Group Therapy on Treatment-Resistant Mental Health Conditions in Firefighters: A Prospective Observational Case Series.

Journal of Occupational and Environmental Medicine June 1, 2025 Vivian Wl Tsang, Michelle Cq Lin, Cassandra M Choles et al. 4 citations

Firefighters display elevated risk for diagnoses of mental health illnesses. Psychedelic-assisted therapies show promise in the treatment of clinically challenging conditions. This observational case series analyzed data from firefighters with mental health diagnoses who participated in a 12-week ketamine-assisted group therapy treatment plan. Questionnaire scores (Generalized Anxiety Disorder...

Rising incidence of recreational ketamine use: Clinical cases and management in emergency settings.

Toxicology Reports June 1, 2025 Sabrina Marongiu, Maarten van Eijk, Femke M J Gresnigt et al. 9 citations

The recreational use of ketamine has risen significantly in the Netherlands, particularly among young adults in nightlife settings. This trend has been accompanied by an increase in first aid incidents involving ketamine, often in combination with other substances such as alcohol or MDMA, leading to heightened toxicity. Acute intoxication with ketamine manifests through symptoms like agitation,...

DOI: 10.1016/j.toxrep.2025.101940 (opens in new tab) Full text (opens in new tab) Emergency medicine Ketamine-induced uropathy Mixed intoxication Toxicological screening +8

Persistent aura without infarction.

Current Opinion in Neurology June 1, 2025 Maurizio Severino, Mark W Green

The scope of this review is to discuss persistent aura without infarction, a rare, highly disabling, yet apparently benign clinical condition, straddling neurology, neuro-ophthalmology, and psychiatry, whose differential diagnosis is essential for an appropriate therapeutic approach and to avoid clinical complications. Here we attempt to report on the available literature, trying to present a...

DOI: 10.1097/WCO.0000000000001357 (opens in new tab) Full text (opens in new tab) Ketamine Migraines and headaches Neurological disorders Migraine treatments +8

Molecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD.

Psychopharmacology June 1, 2025 Nathan J Wellington, Ana P. Bouças, Jim Lagopoulos et al. 16 citations

Existing studies predominantly focus on the molecular and neurobiological mechanisms underlying Ketamine's acute treatment effects on post-traumatic stress disorder (PTSD). This emphasis has largely overlooked its sustained therapeutic effects, which hold significant potential for the development of targeted interventions. This systematic review examines the pharmacokinetic and pharmacodynamic...

Measuring suicidal behavior in the era of rapid-acting antidepressants: A systematic review of ketamine studies.

Psychiatry Research June 1, 2025 Flávia Vieira, Ana Teresa Caliman-Fontes, Breno Souza-Marques et al.

Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically summarize and discuss the currently used instruments for assessing suicidal behavior in the context of ketamine and its enantiomers. We searched Medline/PubMed, Embase, and PsycINFO databases for ketamine (and its enantiomers) human studies exploring...

Ketamine infusion for pain control in severely injured patients: Results of a randomized controlled trial.

The journal of trauma and acute care surgery June 1, 2025 Thomas W Carver, William J Peppard, Jaclyn A Gellings et al. 3 citations

Opiate-based pain regimens remain the cornerstone of pain management following traumatic injury, but issues related to opioids have driven research into alternative analgesics. Adjunctive ketamine has been increasingly used to decrease opioid use, but little evidence exists to support its efficacy within the trauma population. A prospective, randomized, double-blind placebo-controlled trial of...

DOI: 10.1097/TA.0000000000004602 (opens in new tab) Full text (opens in new tab) Opioids Pain management Severe injury Trauma care +3

Single subanesthetic dose of ketamine exerts antioxidant and antidepressive-like effect in ACTH-induced preclinical model of depression.

Molecular and cellular neurosciences June 1, 2025 Ana Ivanović, Jelena Petrović, Dušanka Stanić et al. 3 citations

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and oxidative stress represent important mechanisms that have been implicated in etiopathology of depression. Although first antidepressants were introduced in clinical practice more than six decades ago, approximately 30 % of patients with a diagnosis of depression show treatment resistance. A noncompetitive N-methyl-d-aspartate...

Ketamine for unipolar depression: A systematic review of efficacy and safety.

Australasian Psychiatry June 1, 2025 Tharshanan Edwin Peiris, Amrit Pokhrel, Yuvaraj Paudel 2 citations

BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take weeks to show effects, underscoring the need for faster alternatives. Ketamine, originally an anaesthetic, has emerged as a rapid-acting antidepressant.ObjectiveThis systematic review evaluates ketamine's efficacy and safety in unipolar...

Etomidate versus ketamine for in-hospital rapid sequence intubation: a systematic review and meta-analysis.

European Journal of Emergency Medicine June 1, 2025 Mohamed Aziz Daghmouri, Mohamed Ali Chaouch, Mohamed Noomen et al. 8 citations

Rapid sequence intubation (RSI) is a critical procedure in emergency and intensive care settings. Etomidate has been favored for its hemodynamic stability; however, concerns about adrenal insufficiency have prompted interest in ketamine as an alternative induction agent. This systematic review and meta-analysis aimed to compare the effects of etomidate vs ketamine on 30-day survival and other...

Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System.

CNS Drugs June 1, 2025 Sijia Zhang, Houtan Afshar, Peter J. Colvonen et al. 1 citation

Ketamine and esketamine are increasingly used to manage treatment-resistant depression and have also been shown to reduce symptoms of posttraumatic stress disorder (PTSD). Little is known about how common comorbidities in the veteran population, such as traumatic brain injury (TBI) or obstructive sleep apnea (OSA), may influence ketamine and esketamine treatment outcomes. In this retrospective...

DOI: 10.1007/s40263-025-01180-w (opens in new tab) Full text (opens in new tab) Ketamine therapy Veterans mental health PTSD Treatment Depression treatment +1

The sigma-1 receptor: a mechanistically-informed therapeutic target for antidepressants.

Expert Opinion on Therapeutic Targets June 1, 2025 Naomi Xiao, Liyang Yin, Kayla M Teopiz et al. 5 citations

The mechanism of action of antidepressants is not fully ascertained. In addition to monoamines, disparate other effectors are also implicated in the molecular and cellular effects of chronic stress including neurogenesis, neurodifferentiation, and neuroplasticity. Evidence suggests sigma-1 receptors (S1Rs) as a putative target and possible mediator of antidepressant activity. Data from...

Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics.

Drug Discovery Today June 1, 2025 Sara Castanheira, Catarina Vale Gomes, Joana Bicker et al. 9 citations

The discovery of the rapid antidepressant action of ketamine accelerated the identification of new molecules that are associated with fast and prolonged relief of depressive symptoms. As a result, a new group of antidepressants have emerged, some of them already approved for clinical use, classified as rapid-acting antidepressant drugs (RAADs). Potentiation of brain-derived neurotrophic factor...

The Nine Lives of Ketamine: From CI-581 to Present Day Clinical Application-Commentary on Domino et al.

Clinical Pharmacology & Therapeutics June 1, 2025 Evan D Kharasch 4 citations

The classic article by Domino et al. was the first clinical report and presented the first-in-human study of what would become the drug ketamine. Ketamine has become an analgesic, anesthetic, antidepressant, and drug of misuse. It remains today the only "dissociative anesthetic". It has challenged classical pharmacologic theory and drug development paradigms. The first report on CI-581 could...

DOI: 10.1002/cpt.3634 (opens in new tab) Full text (opens in new tab) Anesthesia Psychopharmacology Mental health Drug development